[go: up one dir, main page]

WO2004092189A1 - Derives d'acide 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonique et leur utilisation comme antagonistes du recepteur n-methyl-d-aspartate (nmda) - Google Patents

Derives d'acide 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonique et leur utilisation comme antagonistes du recepteur n-methyl-d-aspartate (nmda) Download PDF

Info

Publication number
WO2004092189A1
WO2004092189A1 PCT/US2004/010596 US2004010596W WO2004092189A1 WO 2004092189 A1 WO2004092189 A1 WO 2004092189A1 US 2004010596 W US2004010596 W US 2004010596W WO 2004092189 A1 WO2004092189 A1 WO 2004092189A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
ethyl
dioxo
compound
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/010596
Other languages
English (en)
Inventor
Reinhardt Bernhard Baudy
John Anthony Butera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33299828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004092189(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT04759168T priority Critical patent/ATE481103T1/de
Priority to JP2006509747A priority patent/JP4621659B2/ja
Priority to EP04759168A priority patent/EP1611144B1/fr
Priority to CA002521313A priority patent/CA2521313A1/fr
Priority to AU2004230895A priority patent/AU2004230895B2/en
Priority to DK04759168.0T priority patent/DK1611144T3/da
Priority to BRPI0409255-4A priority patent/BRPI0409255A/pt
Priority to CN200480009542XA priority patent/CN1863810B/zh
Priority to DE602004029146T priority patent/DE602004029146D1/de
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to MXPA05010760A priority patent/MXPA05010760A/es
Priority to PL04759168T priority patent/PL1611144T3/pl
Priority to SI200431536T priority patent/SI1611144T1/sl
Publication of WO2004092189A1 publication Critical patent/WO2004092189A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to derivatives of [2-(8,9-dioxo-2,6-diazabicyclo- [5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof.
  • the compounds of the present invention are particularly useful as N-methyl-D-aspartate
  • excitatory amino acid receptors There are at least four classes of excitatory amino acid receptors: NMDA, AMPA (2-amino-3- (methyl-3-hydroxyisoxazol-4-yl)propanoic acid), kainate and metabotropic receptors.
  • NMDA neuropeptide-binding protein
  • NMDA receptors are localized throughout the central nervous system.
  • NMDA receptors are ligand-gated cation channels that modulate sodium, potassium and calcium ions flux when they are activated by glutamate in combination with glycine.
  • the NMDA receptor is thought to be comprised of heteromultimeric channels containing two major subunits designated as NR1 and NR2.
  • the NMDA receptor also contains an Mg ++ binding site located inside the pore of the ionophore of the NMDA receptor/channel complex, which blocks the flow of ions.
  • NMDA N- methyl-D-aspartate
  • NMDA receptor has therapeutic potential for treating numerous disorders.
  • Disorders believed to be responsive to inhibition of NMDA receptors include cerebral vascular disorders such as cerebral ischemia (e.g., stroke) or cerebral infarction resulting in a range of conditions such as thromboembolic or hemorrhagic stroke, or cerebral vasospasm; cerebral trauma; muscular spasm; and convulsive disorders such as epilepsy or status epilepticus.
  • NMDA receptor antagonists may also be used to prevent tolerance to opiate analgesia or to help control symptoms of withdrawal from addictive drugs.
  • NMDA receptor antagonists Screening of compounds in recent years have identified a number of NMDA receptor antagonists that have been used in animal and clinical human studies to demonstrate proof of concept for the treatment of a variety of disorders.
  • the difficulty with demonstrating clinical utility of NMDA receptor antagonists has generally been the antagonists' lack of NMDA receptor subtype selectivity and/or biological activity when dosed orally.
  • the search for NMDA receptor antagonists that are subtype-selective and/or orally efficacious continues.
  • the present invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof:
  • R-t is hydrogen, a C to C 6 alkyl group, a C 2 to C 7 acyl group, a Ci to C 6 alkanesulfonyl group, or a C 6 to C 14 aroyl group;
  • A is alkylene of 1 to 4 carbon atoms or alkenylene of 2 to 4 carbon atoms; R 2 and R 3 are independently selected from hydrogen, or
  • R 4 and R 5 are independently selected from hydrogen, a C T to C 4 alkyl group, a C 5 to C 7 aryl group, a C 6 to C 15 alkylaryl group having 5 to 7 carbon atoms in the aryl ring, a C 2 to C 7 alkenyl group, or C 2 to C 7 alkynyl group, or R 4 and R 5 may together form a spiro C 3 to C 8 carbocyclic ring;
  • R ⁇ is a C 1 to C 12 linear or branched alkyl group, a C 2 to C 7 linear or branched alkenyl or alkynyl group, a C 5 to C 13 aryl group, a C 6 to C 21 alkylaryl group having 5 to 13 carbon atoms in the aryl moiety; a 5 to 13 membered heteroaryl group, a 6 to 21 membered alkylheteroaryl group having 5 to 13 members in the heteroaryl moiety, a C 4 to C 8 cycl
  • R 7 and R 8 are independently selected from hydrogen, a C 1 to C 12 linear or branched alkyl group, a C 2 to C 7 linear or branched alkenyl or alkynyl group, a C 5 to C 13 aryl group, a C 6 to C 21 alkylaryl group having 5 to 13 carbon atoms in the aryl moiety, a 5 to 13 membered heteroaryl group, a 6 to 21 membered alkylheteroaryl group having 5 to 13 members in the heteroaryl moiety, or R 7 and R 8 may together form a cycloalkyl or heterocycloalkyl group having in the ring 4 to 8 carbon atoms and optionally one to two atoms selected from nitrogen, oxygen or sulfur; wherein any R ⁇ to R 8 group having an aryl, heteroaryl, cycloalkyl or heterocycloalkyl moiety may optionally be substituted on the aryl, heteroaryl, cycloalkyl or heterocycloalkyl moiety
  • the present invention provides a method for treating one or more conditions in a mammal that includes administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • conditions that may be treated in accordance with the methods of the present invention include cerebral vascular disorders such as cerebral ischemia or cerebral infarction; cerebral trauma; muscular spasm; convulsive disorders such as epilepsy or status epilepticus; glaucoma; pain; anxiety disorders; mood disorders; schizophrenia; schizophreniform disorder; schizoaffective disorder; cognitive impairment; chronic neurodegenerative disorders such as Parkinson's disease, Huntingdon's disease, Alzheimer's disease, amyotrophic lateral sclerosis, or chronic dementia; inflammatory diseases; hypoglycemia; diabetic end organ complications; cardiac arrest; asphyxia anoxia; spinal chord injury; fibromyalgia, complications from herpes zoster (shingles) such as prevention of post-herpetic neuralg
  • a pharmaceutical composition in another embodiment, includes at least one compound of formula (I) and at least one pharmaceutically acceptable carrier.
  • a product is provided that is made by the process that includes reacting a compound of formula (II)
  • R T is hydrogen, a C 1 to C 6 alkyl group, a C 2 to C 7 acyl group, a d to C 6 alkanesulfonyl group, or a C 6 to C 14 aroyl group;
  • A is alkylene of 1 to 4 carbon atoms or alkenylene of 2 to 4 carbon atoms; R 2 and R 3 are independently selected from hydrogen, or
  • R 4 and R 5 are independently selected from hydrogen, a C 1 to C 4 alkyl group, a C 5 to C 7 aryl group, a C 6 to C 15 alkylaryl group having 5 to 7 carbon atoms in the aryl ring, a C 2 to C 7 alkenyl group, or C 2 to C 7 alkynyl group, or R 4 and R 5 may together form a spiro C 3 to C 8 carbocyclic ring;
  • R 6 is a Ci to C 12 linear or branched alkyl group, a C 2 to C 7 linear or branched alkenyl or alkynyl group, a C 5 to C 13 aryl group, a C 6 to C 21 alkylaryl group having 5 to 13 carbon atoms in the aryl moiety; a 5 to 13 membered heteroaryl group, a 6 to 21 membered alkylheteroaryl group having 5 to 13 members in the heteroaryl moiety, a C 4 to C 8 cycloalkyl group, a C 5 to C 16 alkylcycloalkyl group having 4 to 8 carbon atoms in the cycloalkyl ring;
  • R 7 and R 8 are independently selected from hydrogen, a Ci to C 12 linear or branched alkyl group, a C 2 to C 7 linear or branched alkenyl or alkynyl group, a C 5 to C 13 aryl group, a C 6 to C 21 alkylaryl group having 5 to 13 carbon atoms in the aryl moiety, a 5 to 13 membered heteroaryl group, a 6 to 21 membered alkylheteroaryl group having 5 to 13 members in the heteroaryl moiety, or R 7 and R 8 may together form a cycloalkyl or heterocycloalkyl group having in the ring 4 to 8 carbon atoms and optionally one to two atoms selected from nitrogen, oxygen or sulfur; or a pharmaceutically acceptable salt thereof. Unless otherwise indicated:
  • Alkyl or alkylene as used herein refers to an aliphatic hydrocarbon chain having 1 to 12 carbon atoms and includes, but is not limited to, straight or branched chains such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, and isohexyl.
  • Lower alkyl refers to alkyl having 1 to 3 carbon atoms. In some embodiments of the invention, alkyl is preferably d to C 8 and more preferably Ci to C 6 .
  • Alkenyl or alkenylene refers to an aliphatic straight or branched hydrocarbon chain having 2 to 7 carbon atoms that may contain 1 to 3 double bonds.
  • alkenylene for A are straight or branched mono-, di-, or polyunsaturated groups such as vinyl, prop-1-enyl, allyl, methallyl, but-1-enyl, but-2-enyl or but-3-enyl.
  • Alkynyl refers to an aliphatic, straight or branched, hydrocarbon chain having 2 to 7 carbon atoms that may contain 1 to 3 triple bonds.
  • Alkanesulfonyl refers to the group R-S(O) 2 - where R is an alkyl group of 1 to 6 carbon atoms.
  • Aryl refers to an aromatic 5- to 13-membered mono- or bi- carbocyclic ring such as phenyl or napthyl.
  • groups containing aryl moieties are monocyclic having 5 to 7 carbon atoms in the ring.
  • Heteroaryl means an aromatic 5- to 3-membered carbon containing mono- or bi- cyclic ring having one to five heteroatoms which independently may be nitrogen, oxygen or sulfur.
  • groups containing heteroaryl moieties are monocyclic having 5 to 7 members in the ring where one to two of the ring members are selected independently from nitrogen, oxygen or sulfur.
  • Groups containing aryl or heteroaryl moieties may optionally be substituted as defined below or unsubstituted.
  • Alkylaryl refers to the group -R-Ar where Ar is aryl as defined above and R is an alkyl moiety having 1 to 8, preferably 1 to 6, and more preferably 1 to 4 carbon atoms. Examples of alkylaryl groups include benzyl, phenethyl, 3- phenylpropyl, and 4-phenyl butyl.
  • Alkylheteroaryl refers to the group -R-hetAr where hetAr is heteroaryl as defined above and R is an alkyl moiety having 1 to 8, preferably 1 to 6, and more preferably 1 to 4 carbon atoms.
  • Cycloalkyl refers to a monocarbocyclic ring having 3 to 8 carbon atoms e.g. cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • Heterocycloalkyl refers to a carbon containing monocyclic ring having 3 to 8 ring members where one to two ring atoms are independently selected from nitrogen, oxygen or sulfur.
  • Groups containing cycloalkyl or heterocycloalkyl moieties may optionally be substituted as defined below or unsubstituted.
  • Alkylcycloalkyl refers to the group -R-cycloalk where cycloalk is a cycloalkyl group as defined above and R is an alkyl moiety having 1 to 8, preferably 1 to 6, and more preferably 1 to 4 carbon atoms.
  • Halogen means fluorine, chlorine, bromine or iodine.
  • Substituted refers to a moiety, such as an aryl, heteroaryl, cycloalkyl or heterocycloalkyl moiety having from 1 to about 5 substituents, and more preferably from 1 to about 3 substituents independently selected from a halogen atom, a cyano, nitro or hydroxyl group, a d-C 6 alkyl group, or a d-C 6 alkoxy group.
  • Preferred substituents are a halogen atom, a hydroxyl group, or a C ⁇ -C 6 alkyl group.
  • R T is preferably H or a d to C 4 alkyl group and more preferably H.
  • A is preferably an alkylene group, -(CH 2 ) n - , where n is 1 to 3, more preferably 1 to 2 and most preferably 2.
  • R 2 and R 3 are preferably independently selected from H or:
  • R 2 and R 3 are not H.
  • R 4 and R 5 are preferably selected from H or a Ci to C 4 alkyl group, and more preferably H or methyl.
  • R 6 is preferably selected from a C 3 to C 10 linear or branched alkyl group, a C 5 to C 7 aryl group, a 5- to 7- membered heteroaryl group, or a cycloalkyl group having in the ring 5 to 7 carbon atoms. In a preferred embodiment R 6 is a C 5 to C 7 aryl group.
  • R 2 and R 3 of formula (I) are H or the moiety (B) or (D),
  • R ⁇ is H or a d to C 4 alkyl group
  • A is an alkylene group having the formula -(CH 2 ) n - , where n is 1 to 3
  • R 2 and R 3 are independently selected from H or:
  • R 2 and R 3 are independently selected from H or a d to C alkyl group
  • R 4 and R 5 are independently selected from H or a d to C alkyl group
  • R 6 is selected from a C 3 to C 10 linear or branched alkyl group, a C 5 to C 7 aryl group, a 5- to 7- membered heteroaryl group, or a cycloalkyl group having in the ring 5 to 7 carbon atoms.
  • R 6 is selected from phenyl, n-hept-4-yl, cyclohexyl, isopropyl and t-butyl.
  • R 7 and R 8 are both methyl.
  • compounds of the present invention include the following compounds: 3- ⁇ 2-[8,9-d ⁇ oxo-2,6-diazabicyclo[5.2.0]non-1 (7)-en-2-yl]ethyl ⁇ -3-oxido-7-oxo-7- phenyl-2,4,6-trioxa-3-phosphahept-1-yl benzoate;
  • the compounds of this invention may contain asymmetric carbon atoms and/or phosphorus atoms, and thus can give rise to optical isomers and diastereoisomers. While shown without respect to stereochemistry in formula (I), the present invention includes such optical isomers and diastereoisomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.
  • an enantiomer substantially free of the corresponding enantiomer refers to a compound which is isolated or separated via separation techniques or prepared free of the corresponding enantiomer.
  • substantially free means that the compound is made up of a significantly greater proportion of one enantiomer. In preferred embodiments, the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments of the invention, the compound is made up of at least about 99% by weight of a preferred enantiomer.
  • Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by methods described herein. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).
  • HPLC high performance liquid chromatography
  • the compounds useful in the present invention also include pharmaceutically acceptable salts of the compounds of formula (I).
  • pharmaceutically acceptable salt it is meant any compound formed by the addition of a pharmaceutically acceptable base and a compound of formula (I) to form the corresponding salt.
  • pharmaceutically acceptable it is meant a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient.
  • the pharmaceutically acceptable salts are alkali metal (sodium, potassium, lithium) or alkaline earth metal (calcium, magnesium) salts of the compounds of formula (I), or salts of the compounds of formula (I) with pharmaceutically acceptable cations derived from ammonia or a basic amine.
  • Examples of the later include, but are not limited to, ammonium, mono-, di-, or trimethylammonium, mono-, di-, or triethylammonium, mono-, di-, or tripropylammonium (iso and normal), ethyldimethylammonium, benzyldimethylammonium, cyclohexylammonium, benzylammonium, dibenzyl- ammonium, piperidinium, morpholinium, pyrrolidinium, piperazinium, 1-methyl- piperidinium, 1-isopropylpyrrolidinium, 1 ,4-dimethylpiperazinium, 1-n-butyl- piperidinium, 2-methylpiperidinium, 1-ethyl-2-methylpiperidinium, mono-, di-, or triethanolammonium, tris-(hydroxymethyl)methylammonium, or phenylmonoethanol- ammonium.
  • salts may be formed when one of R 2
  • the compounds of the present invention can be prepared by synthesizing the compound of the formula (II), where A and R ⁇ are defined as for formula (I)
  • a suitable solvent such as dimethylformamide.
  • suitable solvent it is meant a solvent that the compound of formula (II) is soluble in and nonreactive with.
  • an acid scavenger to react with the acid halide reaction by-product
  • an amine is added to the reaction mixture at preferably ambient temperature.
  • the amine is preferably a sterically hindered secondary or tertiary amine and more preferably a tertiary amine such as diisopropylethylamine.
  • R 4 , R 5 , and R 6 are defined as in formula (I), and Y is leaving group, is added to the reaction mixture.
  • the term "leaving group” refers to a moiety that can be selectively displaced by another moiety, such as by nucleophilic substitution or elimination, during a chemical reaction.
  • leaving groups include moieties that when removed by nucleophilic substitution or elimination are relatively stable in anionic form.
  • Leaving groups are well known in the art and include, for example, halides (e.g., chloride, bromide, and iodide) and alkyl- and arylsulfonates such as mesylate, tosylate, brosylate, nosylate, triflate, and the like.
  • Y is a halogen atom.
  • the reaction mixture is heated from about 50°C to about 80°C, and more preferably from about 65°C to about 75°C for a sufficient reaction time so that the halo ester reacts with the compound of formula (II) to form a compound of formula (I).
  • the reaction time is from about 20 hours to about 40 hours, and more preferably from about 25 hours to about 35 hours.
  • the reaction mixture is preferably cooled to ambient temperature, and the compound of formula (I) is isolated using standard techniques known to those skilled in the art.
  • a preferred isolation method is to partition the reaction mixture between a mild base, such as aqueous sodium bicarbonate, and an organic solvent such as ethyl acetate.
  • the aqueous phase is preferably several times re-extracted with the organic solvent, and the combined organic layers are washed again with a mild base.
  • the organic layers are then dried, for example with brine and over magnesium sulfate, filtered and evaporated.
  • the residue is then preferably flash chromatographed on silica gel using standard techniques to isolate the compound.
  • the compounds of the present invention when administered to mammals, are NMDA antagonists, and are thus useful for treating a variety of disorders that benefit from inhibiting the NMDA receptor in mammals.
  • treating it is meant partially or completely alleviating, inhibiting, preventing, ameliorating and/or relieving the disorder.
  • treating includes partially or completely alleviating, inhibiting or relieving the condition in question.
  • mammals as used herein refers to warm blooded vertebrate animals, such as humans.
  • the present invention provides methods for treating conditions in mammals that would benefit from inhibiting the NMDA receptor that includes administering to a mammal in need thereof a therapeutically effective amount of at least one compound of formula (I).
  • the compounds of the present invention after administration into a mammal, form the corresponding phosphonic acid (i.e., where R2 and/or R3 are hydrogen in formula (I)). It has surprisingly been discovered that compounds of the present invention relative to compounds of formula (II) have improved bioavailability when administered orally to mammals. Additionally, the compounds of the present invention, after administration into mammals, have a unique affinity and selectivity for certain binding sites on the NMDA receptor. This unique affinity and selectivity is believed to provide effective treatment at lower doses and/or cause less side effects at doses to provide the desired treatment. This is particularly evident when the condition being treated is pain.
  • the present invention provides methods for treating conditions associated with glutamate abnormalities that includes administering to a mammal in need thereof a therapeutically effective amount of at least one compound of formula (I).
  • associated with refers to conditions directly or indirectly caused by glutamate abnormalities.
  • Glutamate abnormality refers to any condition produced by a disease or a disorder in which glutamate, typically in increased amounts, is implicated as a contributing factor to the disease or disorder.
  • Conditions believed to be associated with glutamate abnormality include, but are not limited to, cerebral vascular disorders such as cerebral ischemia (e.g., stroke) or cerebral infarction resulting in a range of conditions such as thromboembolic or hemorrhagic stroke, or cerebral vasospasm; cerebral trauma; muscular spasm; convulsive disorders such as epilepsy or status epilepticus; glaucoma; pain; anxiety disorders such as such as panic attack, agoraphobia, panic disorder, specific phobia, social phobia, obsessive compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, separation anxiety disorder, or substance-induced anxiety disorder; mood disorders such as bipolar disorders (e.g., bipolar I disorder, bipolar II disorder, and cyclothymic disorder), depressive disorders (e.g., major depressive disorder, dysthymic disorder, or substance-induced mood disorder), mood episodes (e.g., major depressive episode, manic episode, mixed episode, and hypomanic episode
  • the present invention provides methods for treating each of the aforementioned conditions or combinations of these conditions that includes administering to a mammal in need thereof a therapeutically effective amount of at least one compound of formula (I).
  • the compounds of the present invention are used to treat pain.
  • the pain may be, for example, acute pain (short duration) or chronic pain (regularly reoccurring or persistent).
  • the pain may also be centralized or peripheral.
  • Examples of pain that can be acute or chronic and that can be treated in accordance with the methods of the present invention include inflammatory pain, musculoskeletal pain, bony pain, lumbosacral pain, neck or upper back pain, visceral pain, somatic pain, neuropathic pain, cancer pain, pain caused by injury or surgery such as burn pain or dental pain, or headaches such as migraines or tension headaches, or combinations of these pains.
  • a pain caused by inflammation may also be visceral or musculoskeletal in nature.
  • the compounds useful in the present invention are administered in mammals to treat chronic pain such as neuropathic pain associated for example with damage to or pathological changes in the peripheral or central nervous systems; cancer pain; visceral pain associated with for example the abdominal, pelvic, and/or perineal regions or pancreatitis; musculoskeletal pain associated with for example the lower or upper back, spine, fibromylagia, temporomandibular joint, or myofascial pain syndrome; bony pain associated with for example bone or joint degenerating disorders such as osteoarthritis, rheumatoid arthritis, or spinal stenosis; headaches such migraine or tension headaches; or pain associated with infections such as HIV, herpes zoster (shingles), sickle cell anemia, autoimmune disorders, multiple sclerosis, or inflammation such as osteoarthritis or rheumatoid arthritis.
  • chronic pain such as neuropathic pain associated for example with damage to or pathological changes in the peripheral or central nervous systems; cancer pain; visceral pain associated with for example
  • the compounds useful in this invention are used to treat chronic pain that is neuropathic pain, visceral pain, musculoskeletal pain, bony pain, cancer pain or inflammatory pain or combinations thereof, in accordance with the methods described herein.
  • Inflammatory pain can be associated with a variety of medical conditions such as osteoarthritis, rheumatoid arthritis, surgery, or injury.
  • Neuropathic pain may be associated with for example diabetic neuropathy, peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, lumbar or cervical radiculopathies, fibromyalgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, casualgia, thalamic syndrome, nerve root avulsion, or nerve damage cause by injury resulting in peripheral and/or central sensitization such as phantom limb pain, reflex sympathetic dystrophy or postthoracotomy pain, cancer, chemical injury, toxins, nutritional deficiencies, or viral or bacterial infections such as shingles or HIV, or combinations thereof.
  • the methods of use for compounds of this invention further include treatments in which the neuropathic pain is a condition secondary to metastatic infiltration, adiposis dolorosa, burns or central pain conditions related to thalamic conditions.
  • somatic pain that can be treated in accordance with the methods of the present invention include pains associated with structural or soft tissue injury experienced during surgery, dental procedures, burns, or traumatic body injuries.
  • visceral pain that can be treated in accordance with the methods of the present invention include those types of pain associated with or resulting from maladies of the internal organs such as ulcerative colitis, irritable bowel syndrome, irritable bladder, Crohn's disease, rheumatologic (arthralgias), tumors, gastritis, pancreatitis, infections of the organs, or biliary tract disorders, or combinations thereof.
  • the pain treated according to the methods of the present invention may also be related to conditions of hyperalgesia, allodynia, or both. Additionally, the chronic pain may be with or without peripheral or central sensitization.
  • the compounds useful in this invention may also be used to treat acute and/or chronic pains associated with female conditions, which may also be referred to as female-specific pain.
  • Such groups of pain include those that are encountered solely or predominately by females, including pain associated with menstruation, ovulation, pregnancy or childbirth, miscarriage, ectopic pregnancy, retrograde menstruation, rupture of a follicular or corpus luteum cyst, irritation of the pelvic viscera, uterine fibroids, adenomyosis, endometriosis, infection and inflammation, pelvic organ ischemia, obstruction, intra-abdominal adhesions, anatomic distortion of the pelvic viscera, ovarian abscess, loss of pelvic support, tumors, pelvic congestion or referred pain from non-gynecological causes.
  • the compounds of the present invention may also be used to prevent tolerance to opiate analgesia or to help control symptoms of withdrawal from addictive drugs.
  • the compounds of the present invention can be administered in any way known to those skilled in the art, including for example, by oral or parenteral administration such as by intramuscular, intraperitoneal, epidural, intrathecal, intravenous, subcutaneous, intramucosal such as sublingual or intranasal, vaginal, rectal or transdermal administration.
  • oral or parenteral administration such as by intramuscular, intraperitoneal, epidural, intrathecal, intravenous, subcutaneous, intramucosal such as sublingual or intranasal, vaginal, rectal or transdermal administration.
  • the compounds of the present invention are administered orally, intramucosally or intravenously.
  • intranasal administration reference is made to copending provisional application Ser. No. 60/461 ,571 , filed on April 9, 2003 and U.S. application Ser. No.
  • a therapeutically effective amount is at least the minimal amount of the compound or a pharmaceutically acceptable salt form thereof, which treats the condition in question in a mammal.
  • the therapeutically effective amount will depend on such variables as the particular composition used, the route of administration, the severity of the symptoms, and the particular patient being treated.
  • the physician may, for example, evaluate the effects of a given compound of formula (I) in the patient by incrementally increasing the dosage until the desired symptomatic relief level is achieved. The continuing dose regimen may then be modified to achieve the desired result.
  • the compounds of the present invention are incrementally increased in a patient in an amount of from 3 mg/kg to 1000 mg/kg until the desired symptomatic relief level is achieved.
  • the continuing dose regimen may then be modified to achieve the desired result, with the range for oral dosage being preferably from about 20 mg/day to about 900 mg/day.
  • Similar techniques may be followed by determining the effective dose range for other administration routes such as by intravenous or intramuscular routes based on bioavailability data.
  • the compounds of the present invention may be administered to a mammal with one or more other pharmaceutical active agents such as those agents being used to treat any other medical condition present in the mammal.
  • pharmaceutical active agents include pain relieving agents, anti-angiogenic agents, anti-neoplastic agents, anti-diabetic agents, anti-infective agents, or gastrointestinal agents, or combinations thereof.
  • the one or more other pharmaceutical active agents may be administered in a therapeutically effective amount simultaneously (such as individually at the same time, or together in a pharmaceutical composition), and/or successively with one or more compounds of the present invention.
  • the method of administration of the other pharmaceutical active agent may be the same or different from the route of administration used for the compounds of the present invention.
  • the other pharmaceutical active agents may be administered by oral or parental administration, such as for example, by intramuscular, intraperitoneal, epidural, intrathecal, intravenous, intramucosal such as by intranasal or sublingual, subcutaneous or transdermal administration.
  • oral or parental administration such as for example, by intramuscular, intraperitoneal, epidural, intrathecal, intravenous, intramucosal such as by intranasal or sublingual, subcutaneous or transdermal administration.
  • the preferred administration route will depend upon the particular pharmaceutical active agent chosen and its recommended administration route(s) known to those skilled in the art. A more complete listing of pharmaceutical active agent can be found in the
  • Physicians' Desk Reference 55 Edition, 2001 , published by Medical Economics Co., Inc., Montvale, NJ.
  • Each of these agents may be administered according to the therapeutically effective dosages and regimens known in the art, such as those described for the products in the Physicians' Desk Reference, 55 Edition, 2001 , published by Medical Economics Co., Inc., Montvale, NJ.
  • the compounds of the present invention may be administered to a mammal with one or more other pain relieving agents to treat pain in a mammal.
  • pain relieving agents it is meant any agent that directly or indirectly treats pain symptoms.
  • indirect pain relieving agents include for example anti-inflammatory agents, such as anti- rheumatoid agents.
  • the one or more other pain relieving agents may be administered simultaneously (such as individually at the same time, or together in a pharmaceutical composition), and/or successively with the compounds of the present invention.
  • the compounds of the present invention and the one or more pain relieving agents are administered in a manner so that both are present in the mammal body for a certain period of time to treat pain.
  • the method of administration of the other pain relieving agent may be the same or different from the route of administration used for the compound of the present invention.
  • opioids are preferably administered by oral, intravenous, or intramuscular administration routes.
  • the dosage of the other pain relieving agent administered to the mammal will depend on the particular pain relieving agent in question and the desired administration route. Accordingly, the other pain relieving agent may be dosed and administered according to those practices known to those skilled in the art such as those disclosed in references such as the Physicians' Desk Reference, 55 Edition, 2001 , published by Medical Economics Co., Inc., Montvale, NJ.
  • pain relieving agents examples include analgesics such as non-narcotic analgesics or narcotic analgesics; anti-inflammatory agents such as non-steroidal anti-inflammatory agents (NSAID), steroids or anti-rheumatic agents; migraine preparations such as beta adrenergic blocking agents, ergot derivatives, or isometheptene; tricyclic antidepressants such as amitryptyline, desipramine, or imipramine; anti-epileptics such as gabapentin, carbamazepine, topiramate, sodium valproate or phenytoin; ⁇ 2 agonists; or selective serotonin reuptake inhibitors/- selective norepinepherine uptake inhibitors, or combinations thereof.
  • analgesics such as non-narcotic analgesics or narcotic analgesics
  • anti-inflammatory agents such as non-steroidal anti-inflammatory agents (NSAID), steroids or anti-rheumatic agents
  • agents described hereinafter act to relieve multiple conditions such as pain and inflammation, while other agents may just relieve one symptom such as pain.
  • a specific example of an agent having multiple properties is aspirin, where aspirin is anti-inflammatory when given in high doses, but at lower doses is just an analgesic.
  • the pain relieving agent may include any combination of the aforementioned agents, for example, the pain relieving agent may be a non- narcotic analgesic in combination with a narcotic analgesic.
  • Non-narcotic analgesics useful in the present invention include, for example, salicylates such as aspirin, ibuprofen (MOTRIN ® , ADVIL ® ), ketoprofen (ORUDIS ® ), naproxen (NAPROSYN ® ), acetaminophen, indomethacin or combinations thereof.
  • salicylates such as aspirin, ibuprofen (MOTRIN ® , ADVIL ® ), ketoprofen (ORUDIS ® ), naproxen (NAPROSYN ® ), acetaminophen, indomethacin or combinations thereof.
  • opioid analgesics such as fentenyl, sufentanil, morphine, hydromorphone, codeine, oxycodone, buprenorphine or pharmaceutically acceptable salts thereof or combinations thereof.
  • anti-inflammatory agents examples include but are not limited to aspirin; ibuprofen; ketoprofen; naproxen; etodolac (LODINE ® ); COX-2 inhibitors such as celecoxib (CELEBREX ® ), rofecoxib (VIOXX ® ), valdecoxib (BEXTRA ⁇ ) , parecoxib, etoricoxib (MK663), deracoxib, 2-(4-ethoxy-phenyl)-3-(4- methanesulfonyl-phenyl)-pyrazolo[1 ,5-b]pyridazine, 4-(2-oxo-3-phenyl-2,3-dihydro- oxazol-4-yl)benzenesulfonamide, darbufelone, flosulide, 4-(4-cyclohexyl-2-methyl-5- oxazoly
  • anti-inflammatory agents preferably used for treating rheumatoid arthritis include naproxen, which is commercially available in the form of EC-NAPROSYN ® delayed release tablets, NAPROSYN ® , ANAPROX ® and ANAPROX ® DS tablets and NAPROSYN ® suspension from Roche Labs, CELEBREX ® brand of celecoxib tablets, VIOXX ® brand of rofecoxib, CELESTONE ® brand of betamethasone, CUPRAMINE ® brand penicillamine capsules, DEPEN ® brand titratable penicillamine tablets, DEPO-MEDROL brand of methylprednisolone acetate injectable suspension, ARAVATM leflunomide tablets, AZULFIDIINE EN-tabs ® brand of sulfasalazine delayed release tablets, FELDENE ® brand piroxicam capsules, CATAFLAM ® diclofenac potassium tablets, VOLTAREN
  • immunosuppressants such as GENGRAFTM brand cyclospo ne capsules, NEORAL ® brand cyclospohne capsules or oral solution, or IMURAN ® brand azathioprine tablets or IV injection
  • INDOCIN ® brand indomethacin capsules, oral suspension or suppositories PLA
  • At least one compound of the present invention is administered with at least one opioid analgesic in accordance with the methods previously described herein to treat pain. It has been found that the compounds of the present invention, when administered with at least one opioid analgesic such as morphine, have such beneficial effects as synergistically decreasing pain perception, increasing the duration of pain relief, and/or decreasing adverse side effects.
  • the compounds of the present invention may be administered neat (i.e., as is) or in a pharmaceutical composition containing at least one pharmaceutically acceptable carrier.
  • the present invention also provides pharmaceutical compositions containing a pharmaceutically effective amount of at least one compound of formula (I) or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
  • Preferred compounds to be present in the pharmaceutical compositions of the present invention include those compounds of formula (I) previously described as being preferred.
  • Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable.
  • the pharmaceutical compositions may be administered to a mammal to treat a variety of conditions that would benefit from inhibiting the NMDA receptor as previously described herein.
  • compositions useful in the present invention may be in any form known to those skilled in the art such as in liquid or solid form.
  • the proportion of ingredients will depend on such factors as the solubility and chemical nature of the compound of formula (I) and the chosen route of administration.
  • Such compositions are prepared in accordance with acceptable pharmaceutical procedures, such as described in Remingtons Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985).
  • Pharmaceutical compositions, in addition to containing a therapeutically effective amount of one or more compounds of the present invention and a pharmaceutically acceptable carrier may include one or more other ingredients known to those skilled in the art for formulating pharmaceutical compositions.
  • Such ingredients include for example, flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders, tablet-disintegrating agents, encapsulating materials, emulsifiers, buffers, preservatives, sweeteners, thickening agents, coloring agents, viscosity regulators, stabilizers or osmo-regulators, or combinations thereof.
  • Solid pharmaceutical compositions preferably contain one or more solid carriers, and optionally one or more other additives such as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes or ion exchange resins, or combinations thereof.
  • the carrier is preferably a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions, and optionally, other additives, and compacted into the desired shape and size.
  • Solid pharmaceutical compositions such as powders and tablets, preferably contain up to 99% of the active ingredient.
  • Liquid pharmaceutical compositions preferably contain one or more compounds of the present invention and one or more liquid carriers to form for example solutions, suspensions, emulsions, syrups, elixirs, or pressurized compositions.
  • Pharmaceutically acceptable liquid carriers include for example water, organic solvent, pharmaceutically acceptable oils or fat, or combinations thereof.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators, or combinations thereof.
  • suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators, or combinations thereof.
  • suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators, or combinations thereof.
  • liquid carriers suitable for oral or parenteral administration include water (preferably containing additives such as cellulose derivatives such as sodium carboxy
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be administered parenterally, for example by, intramuscular, intraperitoneal, epidural, intrathecal, intravenous or subcutaneous injection.
  • Pharmaceutical compositions for oral or transmucosal administration may be either in liquid or solid composition form.
  • the compounds of this invention may be administered rectally or vaginally in the form of a conventional suppository.
  • the compounds of this invention may be formulated into an aqueous or partially aqueous solution, which can then be utilized in the form of an aerosol.
  • the compounds of this invention may also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin.
  • the carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices.
  • the creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type.
  • Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable.
  • a variety of occlusive devices may be used to release the active ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.
  • the pharmaceutical composition in addition to containing a compound of the present invention may also contain a therapeutically effective amount of one or more pain relieving agents as previously described herein, and/or a therapeutically effective amount one or more other pharmaceutical active agents as previously described herein.
  • the present invention also provides a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the present invention and a therapeutically effective amount of at least one pharmaceutical active agent, such as a pain relieving agent as previously described.
  • the pharmaceutical composition may contain one or more pain relieving agents that includes an opioid analgesic.
  • the pharmaceutical composition is in unit dosage form, such as tablets or capsules.
  • the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient.
  • the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, pre- filled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • the present invention also provides a pharmaceutical composition in unit dosage form that contains a therapeutically effective unit dosage of at least one compound of the present invention.
  • the preferred unit dosage will depend on for example the method of administration and the condition being treated.
  • a unit dosage for oral administration for treating pain preferably ranges from about 20 mg to about 300 mg of the compound of the present invention.
  • the present invention also provides a therapeutic package for dispensing the compound of the present invention to a mammal being treated.
  • the therapeutic package contains one or more unit dosages of the compound of the present invention and a container containing the one or more unit dosages and labeling directing the use of the package for treating the condition, such as pain, in a mammal.
  • the unit dose is in tablet or capsule form.
  • each unit dosage is in a therapeutically effective amount for treating pain.
  • the reaction mixture was concentrated in vacuo to remove acetonitrile.
  • the remaining phase was neutralized to pH 7 using diluted (1 :10) phosphate buffer and then extracted 3 times with methylene chloride (10 mL, 5 mL, 5 mL).
  • the aqueous phase was concentrated in vacuo to a volume of 7 mL and then subjected in 6 aliquots at 1.2 mL each to a preparative HPLC column packed with Phmesphere 10 C18, 5 x 25 cm. Elution was carried out isocratically at 10% acetonitrile in 10 mmole ammonium acetate.
  • the solvent is removed by vacuum distillation and the residue is partitioned (2x) between water and ether.
  • the organic phase is separated, dried over magnesium sulfate, filtered, and evaporated to dryness.
  • the product obtained is flash chromatographed on 200 g silica gel using 8% methanol / chloroform.
  • the compounds of the present invention were evaluated for their effectiveness to treat pain.
  • Compound [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)- en-2-yl)ethyl]phosphonic acid, a compound of formula (II) was also tested and is reported in Table 1 as Comparative 1.
  • the test methods used herein have been used by others skilled in the art to evaluate the effectiveness of compounds for relieving pain.
  • the ability of compounds to reverse PGE 2 -induced thermal hypersensitivity was assessed using a single dose time-course procedure. Under this procedure, a single dose of the compound to be tested was administered orally (PO) 10, 30, 100 or 300 min before the injection of PGE 2 . Tactile sensitivity was assessed 30 min after PGE 2 injection.
  • T 10 The temperature that produced a half-maximal increase in the tail-withdrawal latency (i.e., T 10 ) was calculated from each temperature-effect curve.
  • the T 10 was determined by interpolation from a line drawn between the point above and the point below 10 sec on the temperature-effect curve.
  • thermal hypersensitivity was defined as a leftward shift in the temperature- effect curve and a decrease in the T 10 value.
  • Reversal of thermal hypersensitivity was defined as a return to baseline of the temperature-effect curve and the T 10 value and was calculated according to the following equation:
  • T 10 dru9+PGE2 is the T 10 after a drug in combination with PGE 2
  • T 10 PGE2 is the T 10 after PGE 2 alone
  • ⁇ 10 Dasel ⁇ ne j s the T 10 under control conditions.
  • a % MPE value of 100 indicates a complete return to the baseline thermal sensitivity observed without the PGE 2 injection.
  • a value of greater than 100% indicates that the compound tested reduced thermal sensitivity more than the baseline thermal sensitivity without the PGE 2 injection.
  • Example 1 under a dose of 10 mg/kg, the %MPE value is 57.2 ⁇ 4.7.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés représentés par la formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci. Dans la formule, R2 et/ou R3 ne représente pas hydrogène. Ces composés constituent des antagonistes du récepteur N-méthyl-D-aspartate (NMDA) et permettent de traiter chez un mammifère diverses affections pour lesquelles une inhibition du récepteur NMDA est bénéfique.
PCT/US2004/010596 2003-04-09 2004-04-07 Derives d'acide 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonique et leur utilisation comme antagonistes du recepteur n-methyl-d-aspartate (nmda) Ceased WO2004092189A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SI200431536T SI1611144T1 (sl) 2003-04-09 2004-04-07 Derivati 2-(8,9-diokso-2,6-diazabiciklo(5.2.0)non-1(7)-en-2-il)alkil fosfonske kisline in njihova uporaba kot antagonisti N-metil-D-aspartat(NMDA) receptorja
BRPI0409255-4A BRPI0409255A (pt) 2003-04-09 2004-04-07 derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda)
EP04759168A EP1611144B1 (fr) 2003-04-09 2004-04-07 Derives d'acide 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonique et leur utilisation comme antagonistes du recepteur n-methyl-d-aspartate (nmda)
CA002521313A CA2521313A1 (fr) 2003-04-09 2004-04-07 Derives d'acide phosphonique 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non- 1(7)-en-2-yl)-alkyl et leurs methodes d'utilisation
AU2004230895A AU2004230895B2 (en) 2003-04-09 2004-04-07 Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as N-methyl-D-aspartate (NMDA) receptor antagonists
DK04759168.0T DK1611144T3 (da) 2003-04-09 2004-04-07 Derivater af 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl-phosphonsyre og deres avendelse som n-methyl-D-aspartat (NMDA)-receptor-antagonister
CN200480009542XA CN1863810B (zh) 2003-04-09 2004-04-07 [2-(8，9-二氧代-2，6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用
AT04759168T ATE481103T1 (de) 2003-04-09 2004-04-07 Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
DE602004029146T DE602004029146D1 (de) 2003-04-09 2004-04-07 Derivate von 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkylphosphonsäure und deren verwendung als n-methyl-d-aspartat- (nmda-) rezeptorantagonisten
JP2006509747A JP4621659B2 (ja) 2003-04-09 2004-04-07 ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸の誘導体およびｎ−メチル−ｄ−アスパルテート（ｎｍｄａ）受容体アンタゴニストとしてのその使用
MXPA05010760A MXPA05010760A (es) 2003-04-09 2004-04-07 Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
PL04759168T PL1611144T3 (pl) 2003-04-09 2004-04-07 Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46149003P 2003-04-09 2003-04-09
US60/461,490 2003-04-09

Publications (1)

Publication Number Publication Date
WO2004092189A1 true WO2004092189A1 (fr) 2004-10-28

Family

ID=33299828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/010596 Ceased WO2004092189A1 (fr) 2003-04-09 2004-04-07 Derives d'acide 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonique et leur utilisation comme antagonistes du recepteur n-methyl-d-aspartate (nmda)

Country Status (19)

Country Link
US (2) US7253153B2 (fr)
EP (1) EP1611144B1 (fr)
JP (1) JP4621659B2 (fr)
CN (1) CN1863810B (fr)
AR (1) AR044013A1 (fr)
AT (1) ATE481103T1 (fr)
AU (1) AU2004230895B2 (fr)
BR (1) BRPI0409255A (fr)
CA (1) CA2521313A1 (fr)
CL (1) CL2004000769A1 (fr)
CY (1) CY1110863T1 (fr)
DE (1) DE602004029146D1 (fr)
DK (1) DK1611144T3 (fr)
ES (1) ES2350449T3 (fr)
MX (1) MXPA05010760A (fr)
PL (1) PL1611144T3 (fr)
PT (1) PT1611144E (fr)
TW (1) TWI349674B (fr)
WO (1) WO2004092189A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345032B2 (en) 2003-10-22 2008-03-18 Wyeth Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl}phosphonic acid and esters thereof
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
WO2008065141A1 (fr) 2006-11-30 2008-06-05 Probiodrug Ag Nouveaux inhibiteurs de glutaminylcyclase
WO2008104580A1 (fr) 2007-03-01 2008-09-04 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
WO2009125366A1 (fr) 2008-04-11 2009-10-15 Actelion Pharmaceuticals Ltd Dérivés de 2-phényl-pyridine substitués
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
WO2011110613A1 (fr) 2010-03-10 2011-09-15 Probiodrug Ag Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
US8288385B2 (en) 2009-04-08 2012-10-16 Actelion Pharmaceuticals Ltd. 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
US8466156B2 (en) 2008-04-11 2013-06-18 Actelion Pharmaceuticals Ltd. 2-phenyl-4-cyclopropyl-pyrimidine derivatives
US8518912B2 (en) 2007-11-29 2013-08-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as P2Y12 receptor antagonists
EP2865670A1 (fr) 2007-04-18 2015-04-29 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
EP3461819A1 (fr) 2017-09-29 2019-04-03 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase
US10730896B2 (en) 2016-09-22 2020-08-04 Idorsia Pharmaceuticals Ltd Crystalline forms
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
CA2583114A1 (fr) * 2004-10-08 2006-04-20 Wyeth Derives d'acide [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonique et leurs methodes de preparation
MX2010002191A (es) * 2007-08-27 2010-03-17 Wyeth Llc Composiciones y metodos que emplean antagonistas nmda para lograr un efecto anestesico limitado.
WO2010036937A1 (fr) * 2008-09-27 2010-04-01 Taraxos Inc. Formulations topiques pour le traitement d’une neuropathie
US9359376B2 (en) 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
US10902020B2 (en) * 2018-06-08 2021-01-26 International Business Machines Corporation Multiple cache processing of streaming data

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5990307A (en) * 1997-08-01 1999-11-23 American Home Products Corporation Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
WO2003031416A2 (fr) * 2001-10-10 2003-04-17 Wyeth Derives de l'acide [[2-(amino-3,4-dioxo-1cyclobutene-1-yl)amino]alkyl] utiles dans le traitement de la douleur

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5124319A (en) 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids
DK124393D0 (da) 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
UA52698C2 (uk) 1996-10-04 2003-01-15 Х. Луннбек А/С Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
KR100606580B1 (ko) 1997-08-01 2006-08-01 와이어쓰 [2-((8,9)-디옥소-2,6-디아자비사이클로[5.2.0]-논-1(7)-엔-2-일)에틸]포스폰산의 제조방법
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US20040082543A1 (en) 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
WO2004091633A1 (fr) * 2003-04-09 2004-10-28 Wyeth Compositions pharmaceutiques pour administration intranasale d'acide phosphonique [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyle] et derives et leurs procedes d'utilisation
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5240946A (en) * 1991-01-22 1993-08-31 American Home Products Corporation ((2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino)alkyl)-acid derivatives
US5990307A (en) * 1997-08-01 1999-11-23 American Home Products Corporation Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
US6011168A (en) * 1997-08-01 2000-01-04 American Home Products Corporation Process for the preparation[2-((8,9)-dioxo-2,6-diazabicyclo[5.2.0]-non-1(7)-en-2-yl)ethy l]phosphonic acid
WO2003031416A2 (fr) * 2001-10-10 2003-04-17 Wyeth Derives de l'acide [[2-(amino-3,4-dioxo-1cyclobutene-1-yl)amino]alkyl] utiles dans le traitement de la douleur

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
CHILDERS W E ET AL: "EAA-090", DRUGS OF THE FUTURE, vol. 27, July 2002 (2002-07-01), pages 633 - 638, XP009035520, ISSN: 0377-8282 *
EISENBERG E J ET AL: "Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, vol. 20, no. 4-7, 2001, pages 1091 - 1098, XP009032139, ISSN: 1525-7770 *
FARQUHAR D ET AL: "Biologically reversible phosphate-protective groups", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 72, no. 3, 1 March 1983 (1983-03-01), pages 324 - 325, XP000650041, ISSN: 0022-3549 *
FARQUHAR D ET AL: "Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 23, 11 November 1994 (1994-11-11), pages 3902 - 3909, XP002293733, ISSN: 0022-2623 *
FRANKOVA D ET AL: "Antiinflammatory effects of phosphonomethoxyethyl analogues of adenine in a model of adjuvant arthritis", NUCLEOSIDES & NUCLEOTIDES, vol. 18, no. 4/5, 1999, pages 955 - 958, XP001008347, ISSN: 0732-8311 *
HATSE S ET AL: "Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells.", MOLECULAR PHARMACOLOGY, vol. 50, no. 5, November 1996 (1996-11-01), pages 1231 - 1242, XP009035544, ISSN: 0026-895X *
KHAN S R ET AL: "Bis(N,N-Dimethylcarbamoyloxymethyl) 2', 3'-dideoxyuridine 5'-monophosphate (DM2-ddUMP): A Potential ddUMP Prodrug", TETRAHEDRON LETTERS, vol. 40, no. 4, 22 January 1999 (1999-01-22), pages 607 - 610, XP004151397, ISSN: 0040-4039 *
KINNEY W A ET AL: "Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 25, 11 December 1992 (1992-12-11), pages 4720 - 4726, XP000986052, ISSN: 0022-2623 *
KINNEY W A: "Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 2, 15 January 1998 (1998-01-15), pages 236 - 246, XP002228850, ISSN: 0022-2623 *
LEFEBVRE I ET AL: "Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dideoxythymidine 5'-monophosphate.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 20, 29 September 1995 (1995-09-29), pages 3941 - 3950, XP002293734, ISSN: 0022-2623 *
LOMBAERT S DE ET AL: "Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 4, 18 February 1994 (1994-02-18), pages 498 - 511, XP000564486, ISSN: 0022-2623 *
MULATO A S ET AL: "Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, no. 7, July 1998 (1998-07-01), pages 1620 - 1628, XP002293740, ISSN: 0066-4804 *
NAESENS L ET AL: "Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)aden ine in mice.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, no. 7, July 1998 (1998-07-01), pages 1568 - 1573, XP002293739, ISSN: 0066-4804 *
OLIYAI R ET AL: "Kinetic studies of the degradation of oxycarbonyloxymethyl prodrug of Adefovir and Tenofovir in solution.", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 20, no. 4-7, April 2001 (2001-04-01), pages 1295 - 1298, XP009035539, ISSN: 1525-7770 *
ROBBINS B L ET AL: "Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, no. 3, March 1998 (1998-03-01), pages 612 - 617, XP002293735, ISSN: 0066-4804 *
STARRETT J E ET AL: "Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 3-u2-(phosphonomethoxy)ethyladenine (PMEA)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 12, 10 June 1994 (1994-06-10), pages 1857 - 1864, XP000564485, ISSN: 0022-2623 *
YUAN L C ET AL: "Degradation kinetics of oxycarbonyloxymethyl prodrugs of phosphonates in solution.", PHARMACEUTICAL RESEARCH, vol. 18, no. 2, February 2001 (2001-02-01), pages 234 - 237, XP009035540, ISSN: 0724-8741 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8809010B2 (en) 2003-05-05 2014-08-19 Probiodrug Ag Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases
US7345032B2 (en) 2003-10-22 2008-03-18 Wyeth Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl}phosphonic acid and esters thereof
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
WO2008065141A1 (fr) 2006-11-30 2008-06-05 Probiodrug Ag Nouveaux inhibiteurs de glutaminylcyclase
EP2481408A2 (fr) 2007-03-01 2012-08-01 Probiodrug AG Nouvelle utilisation d'inhibiteurs glutaminyle cyclase
WO2008104580A1 (fr) 2007-03-01 2008-09-04 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
EP2865670A1 (fr) 2007-04-18 2015-04-29 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
US8518912B2 (en) 2007-11-29 2013-08-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as P2Y12 receptor antagonists
WO2009125366A1 (fr) 2008-04-11 2009-10-15 Actelion Pharmaceuticals Ltd Dérivés de 2-phényl-pyridine substitués
US8058263B2 (en) 2008-04-11 2011-11-15 Actelion Pharmaceuticals Ltd Substituted 2-phenyl-pyridine derivatives
US8466156B2 (en) 2008-04-11 2013-06-18 Actelion Pharmaceuticals Ltd. 2-phenyl-4-cyclopropyl-pyrimidine derivatives
US8288385B2 (en) 2009-04-08 2012-10-16 Actelion Pharmaceuticals Ltd. 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
WO2011110613A1 (fr) 2010-03-10 2011-09-15 Probiodrug Ag Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
US10730896B2 (en) 2016-09-22 2020-08-04 Idorsia Pharmaceuticals Ltd Crystalline forms
US11365209B2 (en) 2016-09-22 2022-06-21 Idorsia Pharmaceuticals Ltd Crystalline forms
US12227532B2 (en) 2016-09-22 2025-02-18 Viatris Asia Pacific Ptd. Ltd. Crystalline forms
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
EP3461819A1 (fr) 2017-09-29 2019-04-03 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase

Also Published As

Publication number Publication date
DK1611144T3 (da) 2010-11-22
EP1611144B1 (fr) 2010-09-15
PL1611144T3 (pl) 2011-03-31
AR044013A1 (es) 2005-08-24
US7879825B2 (en) 2011-02-01
CN1863810A (zh) 2006-11-15
PT1611144E (pt) 2010-11-12
BRPI0409255A (pt) 2006-03-28
US7253153B2 (en) 2007-08-07
JP2006523694A (ja) 2006-10-19
CN1863810B (zh) 2010-12-01
AU2004230895A1 (en) 2004-10-28
TW200504085A (en) 2005-02-01
AU2004230895B2 (en) 2010-09-09
ES2350449T3 (es) 2011-01-24
US20070225257A1 (en) 2007-09-27
CL2004000769A1 (es) 2005-02-04
US20050004080A1 (en) 2005-01-06
MXPA05010760A (es) 2005-12-12
TWI349674B (en) 2011-10-01
CA2521313A1 (fr) 2004-10-28
ATE481103T1 (de) 2010-10-15
JP4621659B2 (ja) 2011-01-26
CY1110863T1 (el) 2015-06-10
DE602004029146D1 (de) 2010-10-28
EP1611144A1 (fr) 2006-01-04

Similar Documents

Publication Publication Date Title
US7879825B2 (en) Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
SG177675A1 (en) Bicyclic aryl sphingosine 1-phosphate analogs
JPS63501956A (ja) 新規ビスホスホン酸誘導体、その製造および用途
US20050004079A1 (en) Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
US7879826B2 (en) Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of making them
EA009993B1 (ru) Производные [[2-(амино-3,4-диоксо-1-циклобутен-1-ил)амино]алкил]кислоты, применяемые для лечения боли
ES2312399T3 (es) Procedimiento para preparar compuestos de 2,3-dihidrobenzofurano opticamente activos.
WO2021129584A1 (fr) Composé antagoniste de pd-l1
CN105008361A (zh) 作为钙通道阻滞剂用于治疗疼痛的的二氮杂*衍生物
TWI810547B (zh) Pd-l1拮抗劑化合物
CA3202256A1 (fr) Cyclohexanecarboxamides substitues, leur preparation et leur application therapeutique
EP0287901B1 (fr) Méthode de traitement de la goutte avec des dérivés de chalcone
CN116997547A (zh) 颗粒蛋白前体调节剂及其使用方法
HK1131127B (en) Binding inhibitor of sphingosine-1-phosphate
HK1131127A1 (en) Binding inhibitor of sphingosine-1-phosphate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2521313

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004759168

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/010760

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006509747

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004809542X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004230895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2081/KOLNP/2005

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004230895

Country of ref document: AU

Date of ref document: 20040407

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004230895

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004759168

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0409255

Country of ref document: BR